CRNX
CrineticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Successful late-stage readouts and favorable regulatory interactions drive rapid adoption in target endocrine indications, justifying significant upside to the anchor price.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +5.6.
What can break
Commercial uptake slower than modeled
Momentum
100
Value
41
Sentiment
7
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $48.00 · Bull $85.00 · Bear $22.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-03 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $82.50
Why
Momentum100 · Δ7d +5.6
Value41 · Δ7d -0.1
Sentiment7 · Δ7d -1.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
100
26% active weight
Current posture
7d trendFlat
Δ7d
+5.6
Δ21d
+82.3
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
7
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.5
Δ21d
-76.2
Why this grade
Composite grade D. Momentum 99.8 / Value 41.1 / Sentiment 6.7
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$8.88B
Beta
0.20
Shares Out
105.84M
P/E (TTM) · Derived
-17.0
P/S (TTM)
2978.43
P/FCF (TTM) · Derived
-19.41
Rev YoY
+2873.4%
EPS YoY
+18.2%
Gross Margin
+70.1%
Op Margin
-31130.2%
Net Debt
-$979.35M
Current Ratio
18.60
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology